MANE logo

MANE
Veradermics Inc

201
Mkt Cap
$4.17B
Volume
220,793.00
52W High
$117.71
52W Low
$17.00
Price
$100.63
MANE Fundamentals
Prev Close
$99.72
Open
$99.27
50D MA
$75.75
Beta
0.00
Avg. Volume
675,104.92
EPS (Annual)
-$2.23
P/B
9.50
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
Key PointsSiren initiated a new position by acquiring 1,505,374 shares of Veradermics; the estimated transaction value is $75.94 million based on quarterly average pricing...
Nasdaq News: Markets·4d ago
News Placeholder
More News
News Placeholder
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced...
Business Wire·4d ago
News Placeholder
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported...
Business Wire·6d ago
News Placeholder
Citi Remains Bullish on Veradermics, Incorporated (MANE)
Citi Remains Bullish on Veradermics, Incorporated (MANE...
Yahoo! Finance: News·8d ago
News Placeholder
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill
Veradermics reported positive top line results from Part A of its Phase II/III 302 trial evaluating VDPHL01, an oral extended-release minoxidil tablet, in men with mild to moderate pattern hair loss...
MarketBeat·15d ago
News Placeholder
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Veradermics, Incorporated (Veradermics) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...
Business Wire·19d ago
News Placeholder
Veradermics Announces Launch of Public Offering
Veradermics, Incorporated (Veradermics) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today...
Business Wire·21d ago
News Placeholder
Veradermics says its hair loss pill passed a late-stage trial, potentially the first oral treatment approved in 30 years
The extended-release minoxidil tablet could be the first FDA-approved oral treatment for pattern hair loss in about 30 years...
Quartz·21d ago
News Placeholder
Futures Flat At All Time Highs Ahead Of Huge Week, Semis Set For 19th Day Of Gains
false
Zero Hedge·21d ago
News Placeholder
Veradermics Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 302 Clinical Trial in Male Pattern Hair Loss
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive...
Business Wire·21d ago
<
1
2
...
>

Latest MANE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.